Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) care teams lack confidence in recognizing …
Despite the availability of a safe and effective recombinant zoster vaccine (RZV) for herpes zoster (HZ), vaccination uptake and series completion remain insufficient, leaving many at-risk individuals—particularly older adults, immunocompromised patients, and underserved populations—vulnerable to preventable disease and its impact …
Lupus nephritis (LN) is one of the most consequential organ manifestations of systemic lupus erythematosus (SLE), occurring in approximately 40% to 60% of patients, most often within the first 5 years of diagnosis, and progressing to end-stage kidney disease in …
Extraintestinal manifestations (EIMs) affect up to one-third of patients with inflammatory bowel disease (IBD) and can significantly contribute to morbidity, impaired quality of life, and long-term disease burden, yet they remain inconsistently recognized and managed in clinical practice. Many gastroenterologists …
Although treatment advances in inflammatory bowel disease (IBD) have improved symptom control, many patients continue to experience progressive structural bowel damage and systemic complications that are not adequately addressed in routine care. Gastroenterologists and multidisciplinary gastrointestinal (GI) care teams often …
Systemic health inequities disproportionately impact underserved racial and ethnic populations, leading to higher morbidity, mortality, and reduced quality of life. Socioeconomic disadvantages, racial bias, and barriers to care contribute to these disparities, yet they often go unnoticed by health care …
The rapidly evolving multiple myeloma (MM) treatment landscape has created unprecedented opportunities, while introducing new complexities for clinicians caring for patients with relapsed/refractory (R/R) disease. In just a few years, bispecific antibodies (BsAbs) have emerged as highly effective treatment options, …
Endometriosis is a chronic inflammatory condition that remains underrecognized and undertreated, leaving many individuals of reproductive age with daily pain and disruption. Patients often face preference‑sensitive decisions about pain management, contraception, and fertility without clear guidance, frequently after years‑long diagnostic …
Despite national recommendations, PrEP remains underutilized in many clinical settings because clinicians often lack confidence, time, and practical workflows to consistently identify candidates and act on eligibility findings. Routine care frequently omits a structured sexual health history and assessment, leading …